Poland· PL-100156785

Stribild

A emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat product containing elvitegravirum + cobicistatum + emtricitabinum + tenofovirum disoproxilum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR09

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedStribildATCJ05AR09REGISTER NO.PL-100156785PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR09 (emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat · ATC J05AR09

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Elvitegravirum + Cobicistatum + Emtricitabinum + Tenofovirum disoproxilum
Manufacturer
Gilead Sciences Ireland UC
Country
Poland (PL)
ATC code
J05AR09
ATC class
Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991069599
  • gtin
    05909991069605

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Stribild
  • Liechtenstein · Stribild
  • Norway · Stribild

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/94ed7ed0-2baf-4d06-8fee-b92a63888fd2
GET /v1/drugs/94ed7ed0-2baf-4d06-8fee-b92a63888fd2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg + 150 mg + 200 mg + 245 mg",
  "packaging": "05909991069599 ¦ Rpz ¦ EU/1/13/830/001 ¦ 28066\n1 butelka 30 tabl.\n05909991069605 ¦ Rpz ¦ EU/1/13/830/002 ¦ 34628\n3 butelki 30 tabl.",
  "substance": "Elvitegravirum 150 mg + Cobicistatum 150 mg + Emtricitabinum 200 mg + Tenofovirum disoproxilum 245 mg",
  "common_name": "Elvitegravirum + Cobicistatum + Emtricitabinum + Tenofovirum disoproxilum",
  "pl_product_id": "100156785",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.